VeriMomIst dihydroquercetin in der Schwangerschaft sicher?
No harmonised CLP reproductive classifications (no H360/H361) and no CIR or SCCS safety assessment indicating reproductive hazard. Peer‑reviewed literature on taxifolin (dihydroquercetin) reports antioxidant and pharmacologic effects but does not provide evidence of teratogenicity or reproductive toxicity in humans; ECHA entries are registrations/self‑notifications without harmonised reproductive classification. Dermal exposure from cosmetics is expected to be low but measurable based on compound physicochemistry and cosmetic use patterns (PubChem; ECHA registration dossiers; PubMed).
Pregnancy-safe products containing dihydroquercetin
Related ingredients
Frequently asked questions
- Ist dihydroquercetin in der Schwangerschaft sicher?
- No harmonised CLP reproductive classifications (no H360/H361) and no CIR or SCCS safety assessment indicating reproductive hazard. Peer‑reviewed literature on taxifolin (dihydroquercetin) reports antioxidant and pharmacologic effects but does not provide evidence of teratogenicity or reproductive toxicity in humans; ECHA entries are registrations/self‑notifications without harmonised reproductive classification. Dermal exposure from cosmetics is expected to be low but measurable based on compound physicochemistry and cosmetic use patterns (PubChem; ECHA registration dossiers; PubMed).
- Ist dihydroquercetin während des Stillens sicher?
- No evidence of reproductive or lactation toxicity or of mechanisms that would specifically target lactation transfer. No harmonised classifications or regulatory warnings for breastfeeding. Systemic exposure from topical use is expected to be low but measurable; transfer into breast milk is not documented in the literature.
- Ist dihydroquercetin sicher für Babyhaut?
- No infant‑specific reproductive or developmental toxicity data identified. Hazard and mechanistic evidence for developmental effects are absent. Exposure score increased for baby skin because infant/young child skin has higher surface‑area‑to‑weight and a less mature barrier, so low/measurable adult dermal absorption is plausibly higher in infants (PubChem; ECHA registration dossiers; PubMed).
- Wie bewertet VeriMom dihydroquercetin?
- VeriMom bewertet dihydroquercetin mit 93/100 (keine bekannten Risiken) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu dihydroquercetin?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu dihydroquercetin basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.